Summary of Key Points Core Viewpoint - 医渡科技 has been actively repurchasing its shares, indicating confidence in its market position and future prospects [1] Group 1: Share Buyback Activity - On October 17, 医渡科技 spent HKD 1.013 million to repurchase 181,000 shares [1] - This week, the company has conducted three buybacks totaling approximately 2.685 million shares, with a total expenditure exceeding HKD 15.6 million [1] - Since September 26, the company has executed five buybacks, amounting to around 3.373 million shares and nearly HKD 20 million in total [1] Group 2: Southbound Capital Inflows - On October 14, southbound funds net purchased HKD 34.7273 million worth of 医渡科技 shares, marking the highest net inflow since September 1, 2025 [1] - The net buying has continued for three consecutive days, with a cumulative net purchase of HKD 57.79 million [1] Group 3: Product Development and Market Support - Recently, the world's first topical treatment for proliferative superficial infantile hemangioma, Timolol Maleate Gel, has been approved for market release [1] - 医渡科技 provided critical market research and project analysis services that supported the drug's development and market entry [1]

Core Insights - Beijing Meisen Pharmaceutical announced the approval of the world's first topical treatment for proliferative superficial infantile hemangiomas, Timolol Maleate Gel, by the National Medical Products Administration (NMPA) on September 30, 2025 [1][2] - The successful launch of Timolol Maleate Gel demonstrates China's capability to transition from imitation to original innovation in the pharmaceutical industry [2] Group 1: Product Development and Approval - Timolol Maleate Gel is designed for the treatment of proliferative superficial infantile hemangiomas, a common pediatric skin condition that can lead to serious complications if not treated early [1] - The gel was developed by Beijing Meisen Pharmaceutical, which conducted a systematic pharmacokinetic study of Timolol in infants aged 28 to 180 days, marking a first in the international arena [1] Group 2: Market Research and Support - Yidu Technology's project consulting and evaluation team provided critical market research and project analysis services, supporting the drug's development and market entry [1] - The team was involved from the early feasibility study to later clinical strategies, ensuring that each step of the project was based on reliable information [1] Group 3: Industry Impact and Collaboration - Yidu Technology has served over 350 pharmaceutical companies, supporting 686 clinical trials and 275 real-world studies, facilitating the approval of multiple innovative drugs [2] - The collaboration between Yidu Technology and Beijing Meisen Pharmaceutical represents a significant milestone in advancing pediatric drug development [2]